Approval is for use in myelofibrosis patients with anaemia regardless of prior myelofibrosis therapy Nearly all myelofibrosis patients are estimated to develop.
GSK regulatory submission for momelotinib for the treatment of myelofibrosis accepted for review by Japanese regulator ● Regulatory submission included data from pivotal.